Track Recordati Industria Chimica e Farmaceutica S.p.A. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Recordati Industria Chimica e Farmaceutica S.p.A. REC.VI · Stock Open Recordati Industria Chimica e Farmaceutica S.p.A. in new tab

52.75 EUR
P/E
22.16
EPS
2.38
Yield
2.69%
P/B
5.07
ROE
24.85
Beta
0.53
Loading chart...
Key Metrics
P/E22.16
EPS2.38
Book Value10.40
Price to Book5.07
Debt/Equity108.59
% Insiders46.820%
Growth
Revenue Growth0.08%
Earnings Growth0.29%
Dividend
Dividend Yield2.69%
Annual dividends1.42 EUR
Ex-Div. DateMay 18, 2026
Payout56.30%
5y avg Yield2.48%

DCF Valuation

Tweak assumptions to recompute fair value for Recordati Industria Chimica e Farmaceutica S.p.A. (REC.VI)
Currency: EUR
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Recordati Industria Chimica e Farmaceutica S.p.A. Logo Recordati Industria Chimica e Farmaceutica S.p.A. Analysis (REC.VI)

Italy Health Care Official Website Stock

Is Recordati Industria Chimica e Farmaceutica S.p.A. a good investment? Recordati Industria Chimica e Farmaceutica S.p.A. (REC.VI) is currently trading at 52.75 EUR.

In terms of valuation, the stock trades at a P/E ratio of 22.16. This valuation is generally in line with the broader market.

For income investors, Recordati Industria Chimica e Farmaceutica S.p.A. pays a dividend yield of 2.69%. With a payout ratio of 56%, the dividend appears sustainable.

Investor FAQ

Does Recordati Industria Chimica e Farmaceutica S.p.A. pay a dividend?

Yes, it pays an annual dividend of 1.42 EUR (2.69% yield).

What asset class is Recordati Industria Chimica e Farmaceutica S.p.A.?

Recordati Industria Chimica e Farmaceutica S.p.A. is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.

Company Profile

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops Maapliv for maple syrup urine disease; Isturia for endogenous Cushing's syndrome; Cystadrops treatment of the ocular manifestations of cystinosis; Carbaglu for hyperammonemia due to n-acetyl glutamate synthase deficiency; Qarziba for neuroblastoma patients and patients with relapsed or refractory neuroblastoma; and Fotivda for renal cell carcinoma. It also develops Sylvant for idiopathic multicentric castleman diseases; Caphosol for oral mucositis; ENJAYMO for hemolysis in adults with cold agglutinin disease; Zanidip, Zanipress, Vazkepa, and Logimax for hypertension; Urorec and Avodart for symptoms of benign prostatic hyperplasia; and Livazo for dyslipidemia; Combodart/Duodart; Seloken for angina pectoris, myocardial infarction and cardiac rhythm disorders, as well as hypertension and functional heart disorders. In addition, the company offers Procto-Glyveno for internal and external hemorrhoids; Polydexa, Isofra, and Otofa for ear, nose and throat infections; Isturisa, for Cushing's syndrome; Normosang, human hemin; Juxtapid, homozygous familial hypercholesterolemia;Ledaga, mycosis fungoides, T-cell cutaneous lymphoma;Tergynan, an anti-infective for gynecological infections; CitraFleet and Phosphosoda as bowel cleansers; Lomexin for gynecological and dermatological infections; Hexaspray, treatments for the oral cavity; Magnesio Supremo, a dietary supplement; Reaglia for schizophrenia; Eligard for hormone-dependent prostate cancer; and pasireotide in Phase II trial for patients with post-bariatric hypoglycemia, as well as other products. The company was founded in 1926 and is headquartered in Milan, Italy.

Exchange Ticker
FRA (Germany) RER1.F
VIE (Austria) REC.VI
PNK (United States) RCDTF
MIL (Italy) REC.MI
Trades
Dividend Yield
2.69%
5y avg 2.48%
Annual Dividends
1.42EUR
Next Ex. Div Date
May 18, 2026
Payout Ratio
56.30%
Dividend History paid per year (EUR)
Historical Dividends
Year Total Dividends
▸2027
0.74 EUR
May 18, 2027 (estimated) 0.7449
▸2026
1.37 EUR
Nov. 18, 2026 (estimated) 0.6594
May 18, 2026 0.7100
▸2025
1.30 EUR
Nov. 24, 2025 0.6300
May 19, 2025 0.6700
▸2024
1.23 EUR
Nov. 18, 2024 0.6000
May 17, 2024 0.6300
▸2023
1.17 EUR
Nov. 20, 2023 0.5700
May 22, 2023 0.6000
▸2022
1.12 EUR
Nov. 21, 2022 0.5500
May 23, 2022 0.5700
▸2021
1.08 EUR
Nov. 22, 2021 0.5300
May 21, 2021 0.5500
▸2020
1.02 EUR
Nov. 23, 2020 0.5000
May 18, 2020 0.5200
▸2019
0.95 EUR
Nov. 18, 2019 0.4800
April 23, 2019 0.4700
▸2018
0.88 EUR
Nov. 19, 2018 0.4500
April 23, 2018 0.4300
▸2017
0.42 EUR
Nov. 20, 2017 0.4200
Upcoming Dividends
Name Payment Date Status Amount
Recordati Industria Chimica e Farmaceutica S.p.A. May 18, 2026 0.71 EUR
Recordati Industria Chimica e Farmaceutica S.p.A. Nov 24, 2025 0.63 EUR
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion